SCHEMBL7995744

SCHEMBL7995744

COc1cnc(O)c2cc(Cl)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.40
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
GAK O14976 2/20 0.38
RIPK2 O43353 1/20 0.38
COQ8A Q8NI60 1/20 0.38
NLK Q9UBE8 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL883238 0.83 PDE5A (0.43) ABCB11MEN1KMT2AGAKRIPK2
SCHEMBL8184699 0.81 KMT2A (0.42) ABCB11MEN1KMT2AGAKRIPK2
SCHEMBL17188735 0.81 ACHE (0.42) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL13830533 0.80 TDO2 (0.43) GAKCYP1A2AMY1A
SCHEMBL29122012 0.80 PDE5A (0.41) MEN1KMT2AGAKRIPK2COQ8A
SCHEMBL27919960 0.80 TRPV4 (0.40) ABCB11MEN1KMT2AGAKRIPK2
SCHEMBL8273112 0.78 ROCK2 (0.39) ABCB11MEN1KMT2AGAKRIPK2
SCHEMBL3430430 0.78 L3MBTL1 (0.39) ABCB11GAKRIPK2COQ8ANLK
SCHEMBL3478846 0.78 PDE10A (0.47) ALDH1A1MAPTHPGDHTTTDP1
SCHEMBL12054562 0.77 CA1 (0.43) MEN1KMT2AALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2813500-B1 Intermediates for the preparation of hepatitis C virus inhibitors BRISTOL MYERS SQUIBB CO (US) 2016-08-17 EP disclosed
EP-2283018-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-04-13 EP disclosed
EP-2265606-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-10-21 EP disclosed
EP-2813500-A1 Intermediates for the preparation of hepatitis C virus inhibitors Bristol-Myers Squibb Company (US) 2014-12-17 EP disclosed
WO-2011150190-A2 HCV INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ANACOR PHARMACEUTICALS, INC. (US) 2011-12-01 WO disclosed
WO-2009129109-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-22 WO disclosed
WO-2009085659-A1 CRYSTALLINE FORMS OF N-(TERT-BUTOXYCARBONYL)-3-METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-ISOQUINOLINYL)OXY)-N-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOYL)-2-VINYLCYCLOPROPYL)-L-PROLINAMIDE BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-09 WO disclosed
WO-2008060927-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-22 WO disclosed